UB Paderborn / Katalog / Suche / in CDI

Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress

Cancer cell, 2015-01, Vol.27 (1), p.57-71

2015

Link zum Volltext

Verfügbarkeit prüfen

CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors

Proceedings of the National Academy of Sciences - PNAS, 2011-10, Vol.108 (40), p.16663-16668

2011

Link zum Volltext

Verfügbarkeit prüfen

Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Clinical cancer research, 2014-02, Vol.20 (4), p.926-937

2014

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport

Molecular cancer therapeutics, 2014-12, Vol.13 (12), p.2805-2816

2014

Link zum Volltext

Verfügbarkeit prüfen

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity

Oncotarget, 2017-09, Vol.8 (41), p.69219-69236

2017

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma

Haematologica (Roma), 2017-07, Vol.102 (7), p.1247

2017

Link zum Volltext

Verfügbarkeit prüfen

Heterogeneity of the cancer cell line metabolic landscape

Molecular systems biology, 2022-11, Vol.18 (11), p.e11006-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeted profiling of polar intracellular metabolites using ion-pair-high performance liquid chromatography and -ultra high performance liquid chromatography coupled to tandem mass spectrometry: Applications to serum, urine and tissue extracts

Journal of Chromatography A, 2014-07, Vol.1349, p.60-68

2014

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

Journal of medicinal chemistry, 2023-01, Vol.66 (1), p.384-397

2023

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments

Cancer & metabolism, 2016-04, Vol.4 (5), p.6-6, Article 6

2016

Link zum Volltext

Verfügbarkeit prüfen

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3

Journal of medicinal chemistry, 2015-04, Vol.58 (8), p.3611-3625

2015

Link zum Volltext

Verfügbarkeit prüfen

Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer

Cell Metabolism, 2016-01, Vol.23 (1), p.77-93

2016

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

Clinical cancer research, 2022-11, Vol.28 (21), p.4724-4736

2022

Link zum Volltext

Verfügbarkeit prüfen

Crystal structure of an Xrcc4-DNA ligase IV complex

Nature structural & molecular biology, 2001-12, Vol.8 (12), p.1015-1019

2001

Link zum Volltext

Verfügbarkeit prüfen

The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer

Nature genetics, 2021-01, Vol.53 (1), p.16-26

2021

Link zum Volltext

Verfügbarkeit prüfen

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Cancer research (Chicago, Ill.), 2010, Vol.70 (1), p.288-298

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Journal of medicinal chemistry, 2021-10, Vol.64 (19), p.14498-14512

2021

Link zum Volltext

Verfügbarkeit prüfen

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4

Cell reports (Cambridge), 2016-02, Vol.14 (7), p.1590-1601

2016

Link zum Volltext

Verfügbarkeit prüfen

Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters

Scientific reports, 2018-11, Vol.8 (1), p.16804-12, Article 16804

2018

Link zum Volltext

Verfügbarkeit prüfen

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Cancer research (Chicago, Ill.), 2023-12, Vol.83 (23), p.3989

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeted Metabolic Profiling of the Tg197 Mouse Model Reveals Itaconic Acid as a Marker of Rheumatoid Arthritis

Journal of proteome research, 2016-12, Vol.15 (12), p.4579-4590

2016

Link zum Volltext

Verfügbarkeit prüfen

Correction to “Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models”

Journal of medicinal chemistry, 2023-07, Vol.66 (13), p.9223-9224

2023

Link zum Volltext

Verfügbarkeit prüfen

Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit

ACS chemical biology, 2023-02, Vol.18 (2), p.296-303

2023

Link zum Volltext

Verfügbarkeit prüfen

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors

Molecular cancer therapeutics, 2018-11, Vol.17 (11), p.2309-2319

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress

CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors

Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma

Heterogeneity of the cancer cell line metabolic landscape

Targeted profiling of polar intracellular metabolites using ion-pair-high performance liquid chromatography and -ultra high performance liquid chromatography coupled to tandem mass spectrometry: Applications to serum, urine and tissue extracts

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3

Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

Crystal structure of an Xrcc4-DNA ligase IV complex

The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4

Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1

Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Targeted Metabolic Profiling of the Tg197 Mouse Model Reveals Itaconic Acid as a Marker of Rheumatoid Arthritis

Correction to “Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models”

Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors

Suchergebnisse filtern